GPCR Stock Forecast & Price Target

Structure Therapeutics is supported by a differentiated oral GPCR platform that is advancing multiple shots on goal, led by aleniglipron, which delivered up to 16% weight loss at 72 weeks alongside cleaner tolerability, no DILI, and an 88% overall completion rate. The start of Phase 3 ACCOMPLISH and multiple upcoming catalysts, including additional Phase 2 readouts in 2H26 and ACCG-2671 SAD/MAD data showing target engagement, up to 3% weight loss after a single dose, dose-proportional PK, and a six-day half-life, strengthen conviction in the pipeline. With a >$7B peak sales estimate for aleniglipron at a 75% POS and a potential weekly oral amylin franchise emerging, the company’s fundamentals suggest meaningful commercial upside and portfolio diversification.

Structure Therapeutics is a high-risk clinical-stage name whose lead asset, aleniglipron, still needs to prove that promising Phase 2b results can be replicated in larger Phase 3 trials before any approval is possible. Competitive pressure is intense, with several approved GLP-1 therapies and more than 20 additional candidates in development, so the company must show clear differentiation to win share from entrenched big pharma products and may even need a commercial partner. Financially, 2Q26 operating expenses of $119M and a net loss of $106M underscore continuing burn, even though $1.3B of cash is projected to fund operations through YE28, leaving future dilution and execution risk unresolved.